HOME >> BIOLOGY >> NEWS
Millennium and Bayer industrializing drug discovery process through ongoing successful research alliance

More Than 70 disease-relevant validated drug targets moving in to or beyond screening in first two years of collaboration

CAMBRIDGE, Mass. and LEVERKUSEN, Germany, October 24, 2000 --Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) and Bayer AG today announced that they are currently moving more than 70 disease-relevant validated drug targets into high-throughput screening or lead identification in the first two years of their five-year research alliance. The alliance achieved these exceptional advances through joint efforts. The two companies collaborated to streamline the drug discovery process with Millennium industrializing the rapid identification, characterization and validation of target proteins and Bayer conducting large-scale high-throughput screening. This innovative approach to target discovery allows for the categorization of genes with disease relevance and is a key step in the process to enhance the productivity of drug discovery.

The alliance is centered on genomics research that identifies the composition and function of thousands of genes which carry instructions to make proteins the body needs to function. By integrating large-scale genetics, genomics, automation, informatics and drug discovery technologies, Millennium can rapidly search for disease-relevant targets that are promising for drug development. This resulting drug discovery platform, which effectively meets the needs of the research alliance with Bayer, serves all of Millenniums research programs, both internal and partnered, and contributes validated targets to the Companys own drug discovery pipeline.

With the aid of Bayers high-throughput robotic screening technology, the selected targets are incorporated into test systems to search for compounds that show promise for drug development. This screening process can test more than 200,000 such compounds daily.

The progress of the Millennium and Bayer alliance in its first tw
'"/>

Contact: Maureen Suda, Millennium Pharmaceuticals Inc.
617-551-2959
Porter Novelli
23-Oct-2000


Page: 1 2 3

Related biology news :

1. Millenniums LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance
2. Science and Technology at the Millennium: Retrospect or Prospect Focus of AAAS Science and Technology Colloquium, April 11-13 in Washington, DC
3. Millennium and Wyeth-Ayerst announce the discovery of key potassium ion channel modulating proteins
4. Millennium and the Whitehead Institute identify novel protein important in fat absorption
5. Millennium Clones Diet-Induced Obesity Gene
6. Protemix corporation announces discovery of way to repair hearts damaged by diabetes
7. New OHSU lab will speed drug discovery process
8. New discovery may help transplants survive
9. Genetic discovery could dramatically reduce need for liver transplants in children
10. Plant gene discovery could enhance plant growth, reduce fertilizer needs and phosphate pollution
11. Major scientific discovery in cancer research to be honored

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/29/2017)... , March 29, 2017  higi, the health IT ... North America , today announced a ... the acquisition of EveryMove. The new investment and acquisition ... of tools to transform population health activities through the ... data. higi collects and secures data today ...
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Research and Markets has announced the addition of the "Global ... to 2025" report to their offering. ... The Global Biometric Vehicle Access System Market ... the next decade to reach approximately $1,580 million by 2025. ... for all the given segments on global as well as regional ...
Breaking Biology News(10 mins):
(Date:7/27/2017)... ... July 27, 2017 , ... ... businesses to participate in Lajollacooks4u’s popular corporate team building events this summer. ... in Lajollacooks4u’s signature olive oil competition to whet their palettes. Three teams ...
(Date:7/26/2017)... ... July 26, 2017 , ... ... worldwide rights to SQuEEZ heart function analysis software, and an associated pending patent ... was filed April 10, 2014 and uses high resolution cardiac CT to analyze ...
(Date:7/26/2017)... Biosciences Inc., a world leading specialty CRO announced the publication ... early stage (latent) Mycobacterium tuberculosis (Mtb) infection using state-of-the-art ProteoCarta™, ... ... Caprion Biosciences Inc. (CNW Group/Caprion Biosciences) ... The new data, recently published in EbioMedicine ...
(Date:7/26/2017)... Ca (PRWEB) , ... July 25, 2017 , ... ... August 22, attendees will garner a better understanding of the considerations needed for ... CRISPR-Cas9 applications. , The use of CRISPR-Cas9 to create targeted double-strand breaks in ...
Breaking Biology Technology:
Cached News: